Eledon shareholders approve increase in authorized common shares to 300M

Eledon Pharmaceuticals, Inc.

Shareholders approved increase in authorized common stock from 200M to 300M shares (40.79M for, 0.49M against).
Approved amendment to extend officer exculpation protection to fullest extent under Delaware law (30.04M for, 1.29M against).
Elected Class II directors Keith Katkin, Allan Kirk, and John McBride for three-year terms ending 2028.
Ratified Deloitte & Touche as independent auditor for FY2025 (41.31M for, 36k against).
Authorized share increase and officer exculpation amendments became effective June 10, 2025.

item 5.03item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.